{
    "nctId": "NCT00722072",
    "briefTitle": "Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy",
    "officialTitle": "A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy for Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Number of Participants With Progression-free Survival at 4 Months",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of incurable breast cancer\n\n  * Locally advanced or metastatic disease\n* Measurable or evaluable disease\n\n  * Measurable disease is defined as \u2265 1 uni-dimensionally measurable lesion \u2265 20 mm by conventional techniques or \u2265 10 mm by spiral computed tomography(CT) scan\n\n    * Bone-only metastases that can be imaged with bone scan AND magnetic resonance imaging (MRI) or bone scan AND plain x-ray is considered measurable disease\n    * Tumor lesions that are situated in a previously irradiated area are considered measurable only if they are progressing at the time of study entry\n  * Evaluable disease includes unresectable skin/chest wall metastases that can be photographed and whose size can be measured with a ruler\n\n    * Bone-only metastases that can only be imaged using bone scan or malignant pleural effusion(s) only are not considered evaluable disease\n* Previously treated with a third-generation aromatase inhibitor (e.g., letrozole, anastrazole, or exemestane) AND meets one of the following criteria:\n\n  * Progressed during palliative aromatase inhibitor therapy\n  * Recurred during adjuvant aromatase inhibitor therapy\n  * Recurred within 12 months of completing adjuvant aromatase inhibitor therapy\n* Human Epidermal growth factor Receptor 2(HER2/neu)-negative tumor\n\n  * No Human Epidermal growth factor Receptor 2(HER2/neu) overexpression (i.e., tumor staining 3+ by immunohistochemistry \\[IHC\\] or gene amplified by Fluorescence In Situ Hybridization \\[FISH\\])\n* Hormone receptor status:\n\n  * Estrogen receptor and/or progesterone receptor positive, defined as \u2265 10% of malignant cells with positive nuclear staining\n\nPATIENT CHARACTERISTICS:\n\n* Postmenopausal\n* Eastern Cooperative Group(ECOG) performance status 0-1\n* Life expectancy \u2265 16 weeks\n* Neutrophil count \u2265 1,500/mm\\^\u00b3\n* Platelet count \u2265 100,000/mm\\^\u00b3\n* Hemoglobin \u2265 9.0 g/dL\n* Creatinine \\< 2 mg/dL\n* Total bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) and aspartate aminotransferase(AST) \u2264 2.5 times ULN (\u2264 5 times ULN for patients with liver involvement)\n* International Normalized Ratio(INR) \\< 1.5 OR Prothrombin time/ partial thromboplastin time (PT/PTT) normal\n* Left ventricular ejection fraction(LVEF) normal by Multiple Gated Acquisition(MUGA) or ECHO\n* No known allergy to sorafenib tosylate or fulvestrant\n* No cardiac disease, including any of the following:\n\n  * New York Heart Association(NYHA) class III-IV congestive heart failure\n  * Unstable angina (anginal symptoms at rest) or new-onset angina (within the past 3 months)\n  * Myocardial infarction within the past 6 months\n  * Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\n* No uncontrolled hypertension, defined as systolic blood pressure \\> 150 mm Hg or diastolic blood pressure \\> 90 mm Hg despite optimal medical management\n* No thrombotic or embolic events, such as cerebrovascular accident (including transient ischemic attacks), within the past 6 months\n* No known HIV infection or chronic hepatitis B or C infection\n* No infection that requires IV antibiotics or produces a fever \\> 100\u00b0F within the past 72 hours\n* No pulmonary hemorrhage/bleeding event \u2265 Common terminology criteria for adverse events(CTCAE) grade 2 within the past 4 weeks\n* No other hemorrhage/bleeding event \u2265 CTCAE grade 3 within the past 4 weeks\n* No evidence or history of bleeding diathesis or coagulopathy\n* No significant traumatic injury within the past 2 weeks\n* No serious, nonhealing wound, ulcer, or bone fracture\n* No condition that impairs the patient's ability to swallow whole pills\n* No malabsorption problem\n* No second malignancy within the past 5 years, except adequately treated and cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No underlying medical condition that, in the principal investigator's opinion, will make the administration of study drug hazardous or would obscure the interpretation of adverse events\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior chemotherapy for metastatic or unresectable locally advanced breast cancer\n* No prior sorafenib tosylate or other Vascular endothelial growth factor(VEGF)-targeting therapies\n* More than 2 weeks since prior major surgery or open biopsy\n* No concurrent anticoagulation with warfarin or heparin\n* No concurrent Hypericum perforatum (St. John wort) or rifampin\n* No other concurrent anticancer agents, including chemotherapy or biological therapy\n* No other concurrent investigational drugs\n* Concurrent bisphosphonates allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}